leaning in part on Brewer v. Quaker State Oil Refining Corp., 72 F.3d 326, 334 (3d Cir. 1995)
How later courts described this case
- leaning in part on Brewer v. Quaker State Oil Refining Corp., 72 F.3d 326, 334 (3d Cir. 1995)
- the issue was whether plaintiff committed spoliation by producing copies and not originals of requested documents
- in that case, a Confirmation Order entered ten (10) years earlier
Written by the judges who cited it.
The opinion
NOVEMBER 22, 2022
United States Bankruptcy Court
Newark, NJ
By: Juan Filgueiras, Deputy
UNITED STATES BANKRUPTCY COURT
DISTRICT OF NEW JERSEY
In Re Case No.: 19-13448 (VFP)
TRI HARBOR HOLDINGS CORPORATION, et al.,1
Debtor. Chapter: 11
KAVOD PHARMACEUTICALS LLC (f/k/a RISING
PHARMACEUTICALS, LLC, f/k/a RISING
Adv. Pro. No.: 19-2053 (VFP)
PHARMACEUTICALS, INC.) and TRI HARBOR HOLDINGS
CORPORATION (f/k/a ACETO CORPORATION),
Plaintiffs,
v. Judge Vincent F. Papalia
SIGMAPHARM LABORATORIES, LLC,
Defendant.
MEMORANDUM OPINION DENYING WITHOUT PREJUDICE SIGMAPHARM’S
MOTION FOR SANCTIONS FOR SPOLIATION OF EVIDENCE PENDING
RESULTS OF EVIDENTIARY HEARING TO BE COMBINED WITH TRIAL
LOWENSTEIN SANDLER LLP ELLIOTT GREENLEAF, P.C.
Attorneys for Plaintiffs, Kavod Pharmaceuticals LLC (f/k/a Rising Attorneys for Defendant,
Pharmaceuticals, LLC, f/k/a Rising Pharmaceuticals, Inc.) and Tri Sigmapharm Laboratories, LLC
Harbor Holdings Corporation (f/k/a Aceto Corporation) Henry F. Siedzikowski, Esq.
Reynold Lambert, Esq. Andrew Estepani, Esq.
Wojciech F. Jung, Esq. Timothy Myers, Esq.
Gavin J. Rooney, Esq. Elliott Greenleaf, P.C.
One Lowenstein Drive 925 Harvest Drive, Ste. 300
Roseland, New Jersey 07068 Blue Bell, PA 19422
1 The Liquidating Debtors in the chapter 11 cases and the last four digits of each Liquidating Debtor’s taxpayer
identification number are as follows: Tri Harbor Holdings Corporation (f/k/a Aceto Corporation) (0520); Tri Harbor
Chemical Holdings LLC (f/k/a Aceto Agricultural Chemicals LLC, f/k/a Aceto Agricultural Chemicals Corporation)
HONORABLE VINCENT F. PAPALIA
United States Bankruptcy Judge
I. INTRODUCTION
This matter comes before the Court on the motion (the “Motion”) filed by defendant
Sigmapharm Laboratories, LLC (“Sigmapharm”) for: (i) financial and other sanctions for alleged
spoliation of evidence by plaintiffs, which are two of the nine jointly administered Debtor-entities,
Kavod Pharmaceuticals LLC, f/k/a Rising Pharmaceuticals, LLC f/k/a Rising Pharmaceuticals,
Inc. (“Rising”), and Tri Harbor Holdings Corp., f/k/a Aceto Corporation (“Aceto”) (collectively,
the “Plaintiffs”); and (ii) an evidentiary hearing on the Motion. Sigmapharm asserts that Plaintiffs
destroyed or have withheld certain documents that they were required to maintain and produce
under the audit and related provisions of the parties’ June 22, 2006 Master Product Development
and Collaboration Agreement, the Court Orders described below and the common law duty to
preserve documents and information relating to an actual or reasonably foreseeable lawsuit.2 The
Plaintiffs filed an objection that denies Plaintiffs’ allegations in all material respects and asserts
that the Motion is untimely. Sigmapharm has filed a reply.
II. JURISDICTIONAL STATEMENT
The Court has jurisdiction over this matter under 28 U.S.C. § 1334(b) and the Standing
Orders of Reference entered by the United States District Court on July 10, 1984 and amended on
September 18, 2012. This is a core proceeding under 28 U.S.C. § 157(b)(2)(A), (B) [claims
allowance] and (O). In addition, a Bankruptcy Court has “jurisdiction to interpret and enforce its
own prior orders.” Travelers Indem. Co. v. Bailey, 557 U.S. 137, 151 (2009) (in that case, a
Confirmation Order entered ten (10) years earlier). Venue is proper in this Court under 28 U.S.C.
§ 1408. The court issues the following findings of fact and conclusions of law pursuant to Fed. R.
Bankr. P. 7052. To the extent that any of the findings of fact might constitute conclusions of law,
they are adopted as such. Conversely, to the extent that any conclusions of law constitute findings
of fact, they are adopted as such.
III. STATEMENT OF RELEVANT FACTS AND PROCEDURE
A. Preliminary Statement
The dispute between the parties arises from a June 22, 2006 Master Product Development
and Collaboration Agreement (the “Agreement”) for producing, marketing and sharing profits
from the sale of pharmaceuticals. Other details concerning the Agreement and the relationship
between the parties are included in this Court’s October 5, 2021 Opinion that granted in part and
denied in part the parties’ separate motions for summary judgment. Kavod Pharmaceuticals LLC
v. Sigmapharm Labs., LLC (In re Tri Harbor Holdings Corp.), 2021 WL 4877265 (Bankr. D.N.J.
Oct. 5, 2021) (the “Opinion”).3 The findings of fact and conclusions of law from the Opinion are
incorporated herein by reference. To the extent that this summary deviates from the Opinion, the
Opinion controls.
Among the claims that the October 5, 2021 Opinion (and October 6, 2021 Order) left for
trial are those included in Sigmapharm’s Third Counterclaim of its August 19, 2019 Answer to the
Plaintiffs’ Complaint. The Third Counterclaim sought: (i) to compel Plaintiffs to make their books
and records available for Sigmapharm’s inspection; and (ii) to complete an audit of the parties’
profit-sharing under the Agreement as mandated by §§ 1.36, 1.37, 5.3.4, 8.6, 12.5.3 of the
Agreement (generally, the “Audit Requirements”) and as compelled by certain Court Orders
described infra.4 Section 8.6 of the Agreement (“Maintenance of Record; Audits”) provided:
3 The Court signed the Opinion on October 5, 2021 and the accompanying Order on October 6, 2021 but deferred
docketing them until October 18, 2021 to give the parties the opportunity to seek redaction of references to evidentiary
material that they filed under seal. Neither party requested any redaction.
4 Aug. 19, 2019 Answer and Counterclaim ¶¶ 120-29, Dkt. No. 5. As explained in the October 5, 2021 Opinion, the
Third Counterclaim also incorporated by reference or by Exhibit: Sigmapharm Claim Nos. 155-2 and 162-1;
During the term of this Agreement and for a period of at least seven (7)
years after the date of termination of this Agreement, each Party shall keep
complete and accurate records of all expenses incurred by it under this Agreement,
which expenses are to be reimbursed by one or both of the other Parties.5
The October 5, 2021 Opinion (and October 6, 2021 Order) provided in relevant part:
4. The Court GRANTS IN PART and DENIES IN PART Plaintiff[s’] motion for
summary judgment to disallow certain elements of Sigmapharm’s Claim Nos. 155-
2 (which pertains to Aceto) and 162-1 (which pertains to Rising) as follows:
. . .
(B) The Court GRANTS IN PART Plaintiffs’ motion for partial summary
judgment that disgorgement is not an available remedy for breach of the
Agreement; provided, however, that this relief is granted WITHOUT
PREJUDICE to Plaintiffs’ claims for damages resulting from any breach of
the Agreement, including (without limitation) Plaintiffs’ alleged failure to: (i)
allow the audit; (ii) provide appropriate backup documentation; (iii) maintain
necessary and transparent books and records; or (iv) properly perform the
administrative duties under the Agreement, including those that gave rise to the
administrative fee paid to Rising pursuant to the Agreement.6
A July 22, 2022 Sixth Supplemental Joint Scheduling Order required the parties to file
motions in limine by August 12, 2022, originally returnable on October 4, 2022, and fixed an
October 13, 2022 conference to schedule trial dates beginning October 24, 2022 through December
2, 2022.7 The parties timely filed four (4) in limine motions. The Court rescheduled the return
date of the in limine motions (along with the scheduling conference) to October 18, 2022 and then
to November 9, 2022.
Sigmapharm filed the instant Motion on September 22, 2022, to be returnable at the same
time as the in limine motions, and this Motion was adjourned to be heard at the same time as those
Corp., Dkt. No. 2:18-cv-1238 (E.D. Pa.) (the “District Court,” or the “District Court Action”); Sigmapharm’s
Statement of Claims in the Arbitration ordered by the District Court under Arbitration Case No. 01-18-0002-4042; the
October 26, 2018 District Court Order that compelled arbitration and stayed the District Court Action (including
Sigmapharm’s demand for an audit and for a declaration of rights) but compelled Plaintiffs to preserve documents,
“which might arguably be relevant to the audit provision” (internal citation omitted).
5 Sigmapharm Br., Agreement § 8.6, Ex. 5, Dkt. No. 133.
6 Kavod, 2021 WL 4877265, at *45; Oct. 6, 2021 Order ¶ 4(B), Dkt. No. 69. The Court notes that the word “Plaintiffs”
in line 4 of paragraph 4(B) should be “Sigmapharm’s.”
motions. The concluding paragraph of Sigmapharm’s brief seeks damages in “the full amount of
$4 million of available funds for Sigmapharm’s Proofs of Claims and its Counterclaims.”8 That
figure refers to the aggregate $4 million reserve created under the parties’ Stipulation And Consent
Order entered on December 12, 2021 in the main bankruptcy case.9 The sole decretal paragraph of
Sigmapharm’s proposed Order on this Motion expands the relief requested and states in full:
It is hereby ORDERED that Sigmapharm’s Motion for Sanctions for Spoliation of
Evidence and For an Evidentiary Hearing is GRANTED. JUDGMENT is hereby
entered in favor of Sigmapharm and against [Plaintiffs] on all counts of [Plaintiffs’]
Adversary Complaint and Sigmapharm’s Counterclaims. [Plaintiffs’] Objections
to Sigmapharm’s Proofs of Claims are OVERRULED. [Plaintiffs] shall remit to
Sigmapharm the Sigmapharm Rising Cash Reserve and the Sigmapharm Aceto
Cash Reserve (as set forth in [the December 12, 2021 Stipulation and Consent
Order]) within (2) two days of the entry of this Order.10
Because this Motion overlaps in substantial part -- if not entirely -- with the essence of
Sigmapharm’s affirmative claims for damages arising from Plaintiffs’ alleged breach of the Audit
Requirements of the Agreement and Plaintiffs’ defenses to those claims and seeks to add new
theories of claims and damages (“spoliation”) to Sigmapharm’s existing claims based on the same
or very similar underlying allegations, the Court will deny Sigmapharm’s Motion, without
prejudice to its rights to raise these claims again at trial, subject to any objections by Plaintiffs,
including as to the timing of the Motion.
B. Alleged Facts and Past Procedure Relevant to the Spoliation Motion
Sigmapharm alleges at the core of its Motion that Plaintiffs have not produced, for a period
of seven (7) years (since Sigmapharm’s first demand in late 2015 for Plaintiffs to comply with the
Audit Requirements to the present) adequate, neutral and/or third-party proofs of various expenses
8 Sigmapharm Br., at 36, Dkt. No. 133.
9 The full title of this December 12, 2021 Stipulation and Consent Order is Stipulation And Consent Order Regarding
Liquidating Debtors’ Renewed Motion Seeking (I) Estimation of Claim Nos. 155 And 162 Filed By Sigmapharm
Laboratories, LLC For Plan Reserve And Distribution Purposes And (II) Modification Of Prior Consent Order
Related Thereto, Main Dkt. No. 1503.
and deductions that reduced the parties’ shared net profits under the Agreement.11 Sigmapharm
alleges that Plaintiffs’ failure or inability to produce these records violates:
(i) the October 26, 2018 Order issued by the District Court in the Eastern District of
Pennsylvania compelling Plaintiffs to preserve records;12
(ii) the June 7, 2021 Order issued by this Court enforcing the Audit Requirements of
the Agreement;13 and
(iii) the duty to preserve documents and information relating to pending or reasonably
foreseeable litigation.14
In support of its claims, Sigmapharm also relies heavily on the December 18, 2020 deposition
testimony of Eugene Hughes Sr., who served as Vice President of Finance for Rising
Pharmaceuticals, Inc. from June 12, 2017 to April 19, 2019 and who described the type of
document(s) that he deemed necessary to support the expenses and deductions that Sigmapharm
questioned.15 Sigmapharm correlates its demands with Mr. Hughes’s December 18, 2020
testimony as follows:
11 Kavod, 2021 WL 4677265, at *6 (for initial audit demands);
12 Sigmapharm Br., Oct. 26, 2018 Order, Ex. 2, Dkt. No. 133. It is not clear why Sigmapharm believes that the
Bankruptcy Court has direct authority to enforce the October 26, 2018 Order issued by the Eastern District of
Pennsylvania (perhaps Sigmapharm surmises that the incorporation of the October 26, 2018 Order in its August 19,
2019 Counterclaim makes it enforceable in this case).
13 June 7, 2021 Order, Dkt. No. 64.
14 Sigmapharm Br., 24-25, Dkt. No. 133.
Category Hughes Dep. Hughes Description16
Returns 231:16- Certificates of Destruction.17
232:25
CMS 119:6-20 Medicaid state invoice.
222:2-8 Validation of Medicaid state invoice against the price published
by Rising.
Hard copy from accounts payable files.18
Price differential 225:4-19 [not clear from excerpt] Data collected in iContracts is used to
compare wholesale cost to retail price offer.
Rebates 226:2-227:17 Customer contract is first source for determining rebate.
A product-specific rebate is memorialized in a pricing letter.
Chargeback 211:2-24 A pricing letter would memorialize a “pricing event” between
Rising and a customer, compared to published prices in pricing
tables on iContracts.
303-304 [Pages 303-304 were omitted from Exhibits. Sigmapharm
represents that Mr. Hughes testified that a chargeback would be
supported by a credit memo with a copy of a check.]
Although the details are not completely clear from the deposition pages isolated by Sigmapharm,
Mr. Hughes did testify that there should have been at least certain backup documents or
information (often, if not always, in paper form) and not just data entries to justify the expenses
and deductions noted above.
Sigmapharm also complains that Plaintiffs have refused to provide any backup documents
for requested transactions that occurred after Debtors/Plaintiffs sold to Shore Suven Pharma, Inc.
(“Shore Suven”) on April 19, 2019 the pharmaceutical business that Plaintiffs had operated with
Sigmapharm. Although the Shore Suven Asset Purchase Agreement (the “APA”) did not seem to
expressly include the transfer of books and records relating to the Sigmapharm relationships, and
Plaintiffs did not assume and assign the Agreement to Shore Suven, Plaintiffs have apparently
16 These are not exact quotes but paraphrasing of the cited sections of the December 18, 2020 Hughes Deposition
Transcript at Sigmapharm Br., Ex. 23, Dkt. No. 133.
17 Sigmapharm also referenced Hughes Dep. Tr. 325 in the “Returns” row but did not produce that page.
18 Although Hughes appeared to testify that all this reconciliation and comparison could be done on “iContracts,” he
transferred those books and records to Shore Suven nonetheless. Plaintiffs raise the April 19, 2019
closing of the Shore Suven sale as the basis for not producing supporting documents after April
19, 2019 on the grounds that Plaintiffs transferred their liabilities to customers under the
Agreement to Shore Suven, infra, and that they are not seeking as damages those post-closing
liabilities. In their response, Plaintiffs also assert that they kept copies of all Sigmapharm-related
records that could reasonably be duplicated and contracted with Shore Suven for continued access
to everything else related to Sigmapharm.
The relevant sections of the March 31, 2019 Amended and Restated APA docketed
independently on March 31, 2019 (the original APA having been attached to Debtors’ March 8,
2019 Sale Motion as Exhibit B) stated in most relevant part:
1.2 Excluded Assets. Notwithstanding the provisions of Section 1.1,
nothing herein contained shall be deemed to sell, transfer, assign or convey the
Excluded Assets to Buyer, and Sellers shall retain all right, title and interest to, in
and under the Excluded Assets. For all purposes of and under this Agreement, the
term “Excluded Assets” shall mean any right, title or interest in, to or under any of
the following assets: . . .
(b) any Contracts not listed or described on Schedule 1.1(b) (the “Excluded
Contracts”); . . .
(i) all receivables (other than Accounts Receivables), claims or causes of
action related primarily to any Excluded Asset or Excluded Liability, including any
such item to the extent arising under any guarantee, warranty, indemnity or similar
right in favor of any Seller in respect of any Excluded Asset or Excluded Liability;
(m) all rights, claims and causes of action relating to any Excluded Asset or
any Excluded Liability, and any proceeds thereof; . . .
(s) all Inventory that is expired as of the Agreement Date; and
(t) all other assets set forth on Schedule 1.2(t) [not attached].19
19 Mar. 31, 2019 Amended and Restated APA, Main Dkt. No. 258; Debtors’ Mar. 7, 2019 Sale Motion, Shore Suven
APA, Ex. B, Main Dkt. No. 109. Corporate books and records were excluded at 1.2(f), but these would not seem to
Sigmapharm cites the “Appendix,” a short paragraph attached to the document titled
“Sigmapharm’s Sample Requests: Index of Documents Produced by Rising to Date; As of March
1, 2021” (the “Sampling Index”) as evidence of Rising’s improper transfer of records to Shore
Suven.20 On this ledger of 399 entries, Sigmapharm isolates thirteen (13) (and only thirteen (13))
identified as “Post-Sale”).21 For each of these, Rising does not provide a supporting document but
writes, “See Appendix.”22 The Appendix is a single footnote or legend at the end of the Sampling
Index and states in full:
On April 10, 2019, the Bankruptcy Court approved the sale of substantially all of Rising’s
assets to Shore Suven Pharma, Inc. (“Shore Suven”), pursuant to that certain Amended and
Restated Asset Purchase Agreement, dated as of March 31, 2019 (the “APA”). [Chapter 11
Cases, Docket No. 372]. Under the APA, Shore Suven paid $15 million in cash and
assumed certain liabilities, including $122 million of accrued payables. [See APA § 1.3(c);
APA, Schedule 1.3(c) at Rising_SP_00085144]. The liabilities assumed by Shore Suven
included the remaining liabilities Rising owed to its customers for the Sigmapharm
products, including liabilities for returns, Medicaid, and rebates. [See APA, Schedule 1.3(c)
at Rising_SP_00085144; Rising_SP_00049249; Rising_SP_00049250; Rising_SP_
00085208; RISING_SP_00092055; RISING_SP_00091985; RISING_SP_ 00090833].23
Plaintiffs’ response is a mixture of factual allegation and legal argument and, like
Sigmapharm’s, includes prior grievances (some of which included previously unknown
disclosures concerning Plaintiffs’ relationship to the data sought by Sigmapharm, as described
above). Plaintiffs also argue that Sigmapharm’s Motion is an amalgam of prior motions, some of
which the Court denied (as in the May 18, 2021 Order denying without prejudice Sigmapharm’s
motion to compel discovery from Shore Suven);24
Also, as is noted above, in response to Sigmapharm’s allegation that Plaintiffs transferred
significant financial records to Shore Suven, Plaintiffs’ Counsel states that Rising electronically
20 Sigmapharm Br., at 18, Dkt. No. 133.
21 Sigmapharm Br., at 18; Sampling Index, Ex. 29, Dkt. No. 133. This thirteen (13) entries are 171, 173, 300, 311,
321, 329, 364-366, 370, 392-394.
22 Sigmapharm Br., Sampling Index, Ex. 29, Dkt. No. 133.
23 Sigmapharm Br., Sampling Index, Ex. 29, Dkt. No. 133.
24 Pls.’ Obj. ¶¶ 2, 13, Dkt. No. 134; Mar. 19, 2021 Sigmapharm Cross-motion, Dkt. No. 30; May 18, 2021 Order, Dkt.
duplicated any and every record that it gave to Shore Suven that it could reasonably have copied
and that Plaintiffs and Shore Suven have entered multiple amendments to the March 31, 2019 APA
to extend the period through which they must retain records through the present (as governed most
recently by the July 11, 2022 Amendment No. 7 to the Amended and Restated APA).25 Plaintiffs’
Counsel quotes and reiterates its March 24, 2021 statement objecting to Sigmapharm’s motion to
compel Shore Suven for the point that both Plaintiffs and Shore Suven have access to significant
business records:
Prior to the closing of the Amended and Restated Asset Purchase Agreement with
Shore Suven dated as of March 31, 2019 (the “APA”), Plaintiffs copied all
documents and data that could reasonably be copied, including Plaintiffs’ servers.
For those items for which it was not feasible or reasonable to copy, Plaintiffs
negotiated a contractual right under the APA to access documents and data acquired
by Shore Suven, including Rising’s Enterprise Resource Planning (“ERP”) systems
and hard-copy documents stored offsite at Iron Mountain. (APA § 6.2(e), (f).)26
Plaintiffs concur that the Debtors did not assume and assign the June 22, 2006 Agreement
to Shore Suven in the April 19, 2019 sale on the basis that the Agreement had been “terminated”
more than one year before (that is, on March 23, 2018).27
After the parties entered the June 10, 2020 sampling protocol, Plaintiffs charge
Sigmapharm for delaying until October 1, 2020 its production of a Sampling Index from which
Plaintiffs could work.28 As a consequence, by the time it undertook the sampling, Rising had no
employees and had to retain its eventual forensic expert, Alvarez & Marsal, as well as Eugene
Hughes and Shore Suven to answer the sampling request.29
In the course of pursuing spoliation, Sigmapharm’s reply brief delves even more deeply
into issues that should and will be reserved for trial (e.g., analysis of the reports of Plaintiffs’
25 Pls.’ Obj. ¶ 30; July 11, 2022 Amendment No. 7, Ex. K (filed under seal), Dkt. No. 134, referring to the Mar. 31,
2019 Amended and Restated APA, Main Dkt. No. 258.
26 Pls.’ Obj. ¶ 30, Dkt. No. 134, quoting Mar. 24, 2021 Pls.’ Obj., at 10, Dkt. No. 34.
27 Pls.’ Obj. ¶ 31, Dkt. No. 134.
28 Pls.’ Obj. ¶¶ 13-16, Dkt. No. 134.
forensic expert; further narrative of Plaintiffs’ alleged obstruction; complaints about non-
production of specific documents, all of which are disputed by Plaintiffs in every material
respect).30
IV. LEGAL STANDARDS AND ANALYSIS
“Spoliation is ‘the destruction or significant alteration of evidence, or the failure to preserve
property for another's use as evidence in pending or reasonably for[e]seeable litigation.’” Mosaid
Techs. Inc. v. Samsung Elecs. Co., Ltd., 348 F. Supp. 2d 332, 335 (D.N.J. 2004); West v. Goodyear
Tire & Rubber Co., 167 F.3d 776, 779 (2d Cir. 1999) (citing Black’s Law Dictionary 1401 (6th
ed. 1990). Courts emphasize that spoliation encompasses both: (i) affirmative destruction; and
(ii) failure to preserve. Philips Elecs. N.A. Corp. v. BC Tech., 773 F. Supp. 2d 1149, 1194 (D.
Utah 2011). “In most cases, the duty to preserve is triggered by the filing of a lawsuit, but that
duty may arise even before a lawsuit is filed if a party has notice that future litigation is likely.”
Philips, 773 F. Supp. 2d at 1195.
The Plaintiffs argue that the Third Circuit in Bull v. United Parcel Serv., Inc., 665 F.3d 68,
79 (3d Cir. 2012) (leaning in part on Brewer v. Quaker State Oil Refining Corp., 72 F.3d 326, 334
(3d Cir. 1995)) established that the Court must find that the targeted party acted in bad faith through
“actual suppression or withholding of evidence” before imposing sanctions for spoliation. Bull,
665 F.3d at 73-74 (the issue was whether plaintiff committed spoliation by producing copies and
not originals of requested documents). The Third Circuit in Bull reiterated:
Spoliation occurs where:
(i) the evidence was in the party's control;
(ii) the evidence is relevant to the claims or defenses in the case;
(iii) there has been actual suppression or withholding of evidence; and,
(iv) the duty to preserve the evidence was reasonably foreseeable to the party.
Bull, 665 F.3d at 73. The Court reasoned that bad faith is a precondition to sanctioning a party for
spoliation:
[A] finding of bad faith is pivotal to a spoliation determination. This only makes
sense, since spoliation of documents that are merely withheld, but not destroyed,
requires evidence that the documents are actually withheld, rather than—for
instance—misplaced. Withholding requires intent.
Bull, 665 F.3d at 79. Plaintiffs argue that any cases cited by Sigmapharm and predating Bull are
not authoritative on this point.31
Sigmapharm avers that Plaintiffs’ conduct exceeded “grossly negligent” and “was
concertedly intentional”; therefore, Sigmapharm does not argue whether the Court may find
spoliation on mere negligence.32 Sigmapharm cites numerous circumstantial grounds for implying
bad faith.33 Folino v. Hines, 2018 WL 5982448, at *3 (W.D. Pa. Nov. 14, 2018) (citing Bull, 665
F.3d at 79) (a “finding of bad faith is pivotal to a spoliation determination” and “[a] finding of
intent to deprive may be based on circumstantial evidence”) (other internal citation omitted); Bozic
v. City of Wash., Pa., 912 F. Supp. 2d 257, 269 (W.D. Pa. 2012) (after Bull, a party can demonstrate
bad faith by showing that the targeted party acted with “reckless disregard for the consequences
of an intentional and conscious destruction of evidence, previously specially preserved for
purposes of subsequent litigation, at a time when litigation is necessarily foreseeable”);34 Brown
v. Certain Underwriters at Lloyds, London, 2017 WL 2536419, at *4 (E.D. Pa. June 12, 2017),
aff’d, 777 F.3d. App’x 34 (3d Cir. 2019) (targeted party’s failure to explain loss of cellular phone
31 Pls.’ Br. ¶ 54, Dkt. No. 134. Plaintiffs also focus on the standards and sanctions set forth in Fed. R. Civ. P. 37(e)
(“Failure to Preserve Electronically Stored Information”) (“ESI”), but it is not at all clear that Sigmapharm’s requests
for documents and information are limited to ESI. Pls.’ Br. ¶¶ 48-49, Dkt. No. 134.
32 Sigmapharm Br., at 25, Dkt. No. 133.
33 Sigmapharm Br., at 27-28, Dkt. No. 133.
34 The Court in Bozic v. City of Wash., Pa., 912 F. Supp. 2d 257, 269-70 (W.D. Pa. 2012), decided the same year as
Bull, did a quick and thorough job of canvassing opinions that attempted to interpret and to apply it, finding three (3)
unpublished and non-precedential Third Circuit cases reaching mixed results on intent: “[a]lmost all of the district
court cases applying Bull of which this Court is aware have declined to find spoliation where the party's conduct was
no worse than negligent, or where the evidence was lost in the normal course of daily business or other similar
or to take any steps to preserve information on it enabled counterparty to carry its burden that
target had “suppressed or withheld evidence”).
When the Court imposes sanctions for spoliation, the court analyzes:
(1) the degree of fault of the party who altered or destroyed the evidence;
(2) the degree of prejudice suffered by the party seeking sanctions; and
(3) whether there is a lesser sanction that will avoid substantial unfairness to the
aggrieved party and, where the offending party is seriously at fault, will serve
to deter such conduct by others in the future.
Bull, 665 F.3d at 73 n.5 (quoting Schmid v. Milwaukee Elec. Tool Corp., 13 F.3d 76, 79 (3d Cir.
1994)) (paragraphing added in part).
Sanctions for spoliation are meant to serve three (3) functions at once:
(i) a remedial function by leveling the playing field or restoring the prejudiced party
to the position it would have been without spoliation;
(ii) a punitive function, by punishing the spoliator for its actions; and
(iii) a deterrent function, by sending a clear message to other potential litigants that this
type of behavior will not be tolerated and will be dealt with appropriately if need
be.
Centimark Corp. v. Pegnato & Pegnato Roof Mgmt., Inc., 2008 WL 1995305, at *9 (W.D. Pa.
May 6, 2008) (quoted, paragraphing added), citing Mosaid, 348 F. Supp. 2d at 335. The Court in
Jacobs v. City of Pittsburgh, 143 F. Supp. 3d 307, 311 (W.D. Pa. 2015) identified as potential
sanctions for spoliation:
(i) dismissal of a claim . . .
(ii) judgment in favor of the prejudiced party,
(iii) suppression of evidence,
(iv) an adverse inference instruction that the spoiled [spoliated] evidence was
harmful to the offending party's case,
(v) fines, and
(vi) attorneys' fees and costs.
Jacobs, 143 F. Supp. 3d at 311 (quoted, paragraphing added). The Court in Mosaid, 348 F. Supp.
2d at 335, called the fourth sanction the “spoliation inference.”
As a sanction for spoliation, Sigmapharm ultimately seeks (i) judgment; (ii) an adverse
inference; or, if the Court can grant neither (iii) an evidentiary hearing before the Court takes
further action in the adversary proceeding.35
Plaintiffs argue that Sigmapharm’s Motion is untimely and could be denied on that basis
alone.36 Larios v. Lunardi, 442 F. Supp. 3d 1299, 1302-1306 (E.D. Calif. 2020), aff’d, 856 F.
App’x 704 (9th Cir. 2021) (observing that parties should raise spoliation claims “as soon as
reasonably possible after [uncovering] the facts that underlie the motion” and denying spoliation
motion filed after close of discovery and nine (9) months after discovering the alleged spoliation)
(internal citations omitted). Plaintiffs cite a sequence of cases in which Courts denied spoliation
motions within weeks (or even a few months) of trial as “simply too late.” Weber Mfrg. Techs.,
Inc. v. Plasan Carbon Composites, Inc., 2016 WL 8114507, at *4 (E.D. Mich. July 26, 2016)
(Court denied spoliation motion filed over a year after discovery closed and within three (3)
months of trial); TFG-North Carolina, L.P. v. Performance Fibers, Inc., 2011 WL 13238434, at
*3 (D. Utah Jan. 10, 2011) (Court denied spoliation motion filed after due date for dispositive
motions, after final pretrial conference and three weeks before trial). In response, Sigmapharm
argues that it was not in a position to file the Motion earlier because of Plaintiffs’ continuing
production of documents after discovery deadlines had passed. The Court will not deny the Motion
on this ground alone, but finds that this is another area that involves disputed and mixed questions
of fact and law that cannot be resolved on the current record. However, as part of its proofs,
Sigmapharm will have to show that it did not, in fact, wait too long in bringing this Motion.
In this case, and as noted above, there is significant, if not complete, overlap between
Sigmapharm’s spoliation claims and its affirmative claims that Plaintiffs breached the Audit
35 Sigmapharm Br., at 33-35, Dkt. No. 133.
Requirements of the Agreement, as well as Plaintiffs’ defenses to those claims. Further, to find
by clear and convincing evidence that Plaintiffs acted in bad faith and/or with a reckless disregard
for their obligations to preserve documents and other evidence, the Court will require testimony
and/or other evidence that would satisfy that heavy burden, particularly because of the overlap
between factual and legal issues underlying the merits of this case and Sigmapharm’s spoliation
claims (as was the case with Sigmapharm’s motions to exclude the audit packages and certain
documents created post-litigation by Plaintiffs). The need for that testimony and evidence to
determine these issues is heightened in this case by the significant sanctions Sigmapharm asks this
Court to impose -- ranging from outright dismissal of Plaintiffs’ affirmative claims and judgment
in favor of Sigmapharm (for $4 million) -- to adverse inferences. Relatedly, the Court would have
to determine whether the alleged failure to satisfy the Audit Requirements of the Agreement could
lead to more or different damages than would be allowed in a typical breach of contract case.
However, given the advanced stage of these proceedings and the timing of the filing of this Motion,
what this Court will not do is to delay trial of this case pending resolution of this Motion, especially
considering the substantive and substantial overlap between the issues on this Motion and the
merits of the entire case, as noted above.
In sum, the Court will deny Sigmapharm’s Motion without prejudice and subject to an
evidentiary hearing to be combined with the trial for the reasons previously stated above and in
the Court’s related recent decisions that similarly denied without prejudice Sigmapharm’s in limine
motions seeking to exclude evidence of documents created after the start of this litigation and the
audit packages.
V. CONCLUSION
For all the foregoing reasons, the Court will deny without prejudice Sigmapharm’s Motion
for Sanctions for Spoliation of Evidence, pending the results of an evidentiary hearing that will be
combined with the trial of this Adversary Proceeding. All rights and objections of the parties with
respect to the matters at issue on this Motion are preserved.
A conforming Order is being entered contemporaneously with this Opinion.
Date: November 22, 2022 Vincent F. Papabia
VINCENT F. PAPALIA
United States Bankruptcy Judge
16